Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy
- PMID: 21484570
- DOI: 10.1007/978-3-642-17214-4_6
Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy
Abstract
Glucocorticoid action is mediated by glucocorticoid receptor (GR), which upon cortisol binding is activated and regulates the transcriptional expression of _target genes and downstream physiological functions. 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) catalyzes the conversion of inactive cortisone to active cortisol. Since cortisol is also produced through biosynthesis in the adrenal glands, the total cortisol level in a given tissue is determined by both the circulating cortisol concentration and the local 11β-HSD1 activity. 11β-HSD1 is expressed in liver, adipose, brain, and placenta. Since it contributes to the local cortisol levels in these tissues, 11β-HSD1 plays a critical role in glucocorticoid action. The metabolic symptoms caused by glucocorticoid excess in Cushing's syndrome overlap with the characteristics of the metabolic syndrome, suggesting that increased glucocorticoid activity may play a role in the etiology of the metabolic syndrome. Consistent with this notion, elevated adipose expression of 11β-HSD1 induced metabolic syndrome-like phenotypes in mice. Thus, 11β-HSD1 is a proposed therapeutic _target to normalize glucocorticoid excess in a tissue-specific manner and mitigate obesity and insulin resistance. Selective inhibitors of 11β-HSD1 are under development for the treatment of type 2 diabetes and other components of the metabolic syndrome.
Similar articles
-
Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11beta-hydroxysteroid dehydrogenase type 1) gene.Mol Cell Endocrinol. 2008 Mar 26;285(1-2):10-8. doi: 10.1016/j.mce.2008.01.012. Epub 2008 Feb 2. Mol Cell Endocrinol. 2008. PMID: 18313835
-
Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.Minerva Endocrinol. 2007 Sep;32(3):141-59. Minerva Endocrinol. 2007. PMID: 17912154 Review.
-
11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic _target.Minerva Endocrinol. 2005 Mar;30(1):37-46. Minerva Endocrinol. 2005. PMID: 15877012 Review.
-
Recent advances in the discovery of 11beta-HSD1 inhibitors.Curr Opin Drug Discov Devel. 2008 Jul;11(4):495-511. Curr Opin Drug Discov Devel. 2008. PMID: 18600567 Review.
-
Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic _target.Drug Discov Today. 2007 Jul;12(13-14):504-20. doi: 10.1016/j.drudis.2007.06.001. Epub 2007 Jun 27. Drug Discov Today. 2007. PMID: 17631244 Review.
Cited by
-
Presenteeism and Productivity: The Role of Biomarkers and Hormones.Int J Environ Res Public Health. 2021 May 10;18(9):5014. doi: 10.3390/ijerph18095014. Int J Environ Res Public Health. 2021. PMID: 34068466 Free PMC article.
-
Current therapies and emerging drugs in the pipeline for type 2 diabetes.Am Health Drug Benefits. 2011 Sep;4(5):303-11. Am Health Drug Benefits. 2011. PMID: 25126358 Free PMC article. Review.
-
Ligand-based pharmacophore modeling and virtual screening for the discovery of novel 17β-hydroxysteroid dehydrogenase 2 inhibitors.J Med Chem. 2014 Jul 24;57(14):5995-6007. doi: 10.1021/jm5004914. Epub 2014 Jul 10. J Med Chem. 2014. PMID: 24960438 Free PMC article.
-
Novel _targets for potential therapeutic use in Diabetes mellitus.Diabetol Metab Syndr. 2023 Feb 13;15(1):17. doi: 10.1186/s13098-023-00983-5. Diabetol Metab Syndr. 2023. PMID: 36782201 Free PMC article. Review.
-
Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?Endocrine. 2013 Aug;44(1):47-58. doi: 10.1007/s12020-013-9884-3. Epub 2013 Jan 25. Endocrine. 2013. PMID: 23354728 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
